Bausch + Lomb launches Miebo prescription eye drop for dry eye disease
Bausch + Lomb has announced the U.S. commercial launch of Miebo, a perfluorohexyloctane ophthalmic solution designed to treat signs and symptoms of dry eye disease by directly targeting tear evaporation.
According to a company press release, more than 38 million Americans have dry eye disease, with the majority experiencing evaporative dry eye. Miebo is a single-ingredient prescription eye drop free from water, preservatives and steroids that spreads quickly and comfortably, reducing tear evaporation at the ocular surface.
“More and more Americans are suffering from dry eye disease, due in large part to today’s multiscreen lifestyles,” Andrew Stewart, president of global pharmaceuticals at Bausch + Lomb, said in the release. “With Miebo, eye care professionals now have a prescription eye drop that directly addresses tear evaporation, the leading cause of dry eye disease.”
Miebo was approved by the FDA in May 2023, based on results from two phase 3 trials in which the drops significantly improved dry eye signs and symptoms, the release stated. The most common adverse reaction was blurred vision, reported in 1% to 3% of participants along with eye redness.
Read more about